Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06005974 · ClinicalTrials.gov registry record · Phase 2
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
A Phase 2 study, sponsored by Recursion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT06005974 is a Phase 2 study that was terminated before completion, run by Recursion Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT06005974, a Phase 2 study, was terminated before completion, sponsored by Recursion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
Interventions
- DRUG REC-4881
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06005974
The ClinicalTrials.gov registry entry for NCT06005974 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Recursion Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REC-4881 is the first listed.
NCT06005974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06005974 about?
NCT06005974 is a clinical study titled "A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation". This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
What is the current status of trial NCT06005974?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-01-15. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT06005974?
The interventions under investigation include: REC-4881 (DRUG).
Who is sponsoring clinical trial NCT06005974?
This trial is sponsored by Recursion Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.